Product Information
RESTASIS 0.05% EYE EMULSION is a brand product labeled by Allergan, Inc., priced at $10.3125 per EA under NDC 00023916360. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Dec 23, 2002. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the cyclosporine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
.5 mg/mL
Manufacturer
Allergan, Inc.NDC
00023916360
Classification
Brand
Dosage Form
EMULSION
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
CYCLOSPORINEApproval Type
New Drug (NDA)
FDA Application
NDA050790FDA Approved
12/23/2002
TE Code
AB
On Market Since
4/1/2003
Pharmacological Classes
Price Statistics
The NADAC for RESTASIS 0.05% EYE EMULSION has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 115.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.3125 per EA |
|---|---|
| All-time high | $10.3396 (Mar 15, 2023) |
| All-time low | $4.7953 (Nov 28, 2013) |
| 52-week high | $10.3248 |
| 52-week low | $10.3125 |
| Median price | $9.3687 |
| Average price | $8.6571 |
| Largest weekly change | +9.9% (Jan 13, 2016) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 91% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Allergan, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
cyclosporine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcineurin Inhibitor Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RESTASIS 0.05% EYE EMULSION?
The current National Average Drug Acquisition Cost (NADAC) for RESTASIS 0.05% EYE EMULSION, manufactured by Allergan, Inc., is $10.3125 per EA (NDC 00023916360), effective Sep 30, 2026.
How has the price of RESTASIS 0.05% EYE EMULSION changed over time?
Over the history we have for it, the NADAC for RESTASIS 0.05% EYE EMULSION has risen 115.1%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for RESTASIS 0.05% EYE EMULSION?
Since Nov 28, 2013, the NADAC for RESTASIS 0.05% EYE EMULSION has ranged from a low of $4.7953 (Nov 28, 2013) to a high of $10.3396 (Mar 15, 2023), with a median of $9.3687 per EA.
Are there cheaper alternatives to RESTASIS 0.05% EYE EMULSION?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CYCLOSPORINE 0.05% EYE EMULSION, is $0.9094 per EA — about 91% below RESTASIS 0.05% EYE EMULSION.
Who manufactures RESTASIS 0.05% EYE EMULSION?
RESTASIS 0.05% EYE EMULSION (NDC 00023916360) is labeled by Allergan, Inc., and CMS classifies it as a brand product.